Abstract
Glioma are often impossible to visualize discrimination within different grades and staging, especially for glioma molecular subgrouping which is highly related with surgery strategy and prognosis. Based on glioma guideline published on 2021, molecular subgroups such as IDH, 1p/19q etc. need to be detected to classify the subgroups (astrocytoma, oligodendroglioma, GBM) from high-grade glioma and guide the personalized treatment. However, timely intraoperative technology is limited to identify molecular subgroups of glioma tissues. To address this problem, we develop a deep learning-guided fiberoptic Raman diagnostic platform to assess its ability of real-time high-grade glioma molecular subgrouping. The robust Raman diagnostic platform is established using convolutional neural networks (ResNet) together with fingerprint spectra acquired within 3 seconds. We have acquired a total of 2358 Raman spectra from 743 tissue sites (astrocytoma: 151; oligodendroglioma:150; GBM: 442) of 44 high-grade glioma patients (anaplastic astrocytoma: 7; anaplastic oligodendroglioma:8; GBM: 29). The optimized ResNet model provides an overall mean diagnostic accuracy of 84.1% (sensitivity of 87.1% and specificity of 81.5%) for identifying 7 molecular subgroups (e.g., IDH, 1p/19q, MGMT, TERT, EGFR, Chromosome 7/10, CDKN2A/B) of high-grade glioma, which is superior to the best diagnosis performance using PCA-SVM and UMAP. We further investigate the saliency map of the best ResNet models using the correctly predicted Raman spectra. The specific Raman features that are related to the tumor-associated biomolecules (e.g., collagens, and lipids) validate the robustness of ResNet diagnostic model. This potential intraoperative technology may therefore be able to diagnosis molecular subgroups of high-grade glioma in real time, making it an ideal guide for surgical resection and instant post-operative decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (No. 62027824, No. 91959120, and No. 62205010); Beijing Natural Science Foundation (No.7224367 and No. L223018); Fundamental Research Funds for the Central Universities (No. YWF-22-L-547 and No. YWF-22-L-1265).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Beijing Tiantan Hospital and Beihang University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
